Venture Capital News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Venture CapitalNewsZetagen Therapeutics Scores $12.9M Series B1
Zetagen Therapeutics Scores $12.9M Series B1
Venture Capital

Zetagen Therapeutics Scores $12.9M Series B1

•November 25, 2025
0
VC News Daily
VC News Daily•Nov 25, 2025

Why It Matters

The funding validates investor confidence in Zetagen’s novel delivery approach and provides resources to advance three breast‑cancer candidates, potentially reshaping treatment paradigms and creating a new market niche for intratumoral therapies.

Zetagen Therapeutics Scores $12.9M Series B1

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...